GNH USA

Europe — EMA

Nuvaxovid Xbb.1.5 (Matrix M, Mivalsecovatein)

GNH USA supplies Nuvaxovid Xbb.1.5 (Matrix M, Mivalsecovatein), a vaccine for emerging viral infections. Request a quote for global supply.

Matrix M, Mivalsecovatein

Request sourcing

1
Pack/s

What is Matrix M, Mivalsecovatein?

Matrix M, the active ingredient in Nuvaxovid Xbb.1.5, is a vaccine presented as an intramuscular injection for use in the prevention of infectious disease in adults. It is designed to stimulate an immune response against targeted viral antigens. GNH USA supplies Nuvaxovid Xbb.1.5 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Matrix M, Mivalsecovatein used for?

Nuvaxovid Xbb.1.5 is reported to target emerging viral pathogens, aiming to stimulate protective immunity. - Emerging viral infections: intended to provide prophylactic immunity against newly identified viruses. - Respiratory viral infections: aims to reduce incidence of severe disease caused by respiratory viruses. - Pandemic preparedness: used in vaccination campaigns to mitigate spread of novel viral threats.

What are the side effects of Matrix M, Mivalsecovatein?

Adverse reactions may occur following intramuscular administration of Nuvaxovid Xbb.1.5.

Common Side Effects: - Injection site pain - Redness at injection site - Swelling at injection site - Mild fever - Headache - Fatigue

Serious or Rare Side Effects: - Anaphylaxis - Guillain‑Barré syndrome - Severe allergic reaction - Neurological complications

What precautions apply to Matrix M, Mivalsecovatein?

Before using Nuvaxovid Xbb.1.5, consider the following precautions. - Pregnancy: safety not established; consult a healthcare provider before vaccination. - Breastfeeding: unknown; evaluate benefits versus potential risks. - Immunocompromised patients: may have reduced immune response to the vaccine. - Allergy: avoid if known hypersensitivity to any vaccine component. - Concurrent vaccination: schedule according to national immunization guidelines. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

What does Matrix M, Mivalsecovatein interact with?

Potential drug interactions should be reviewed prior to administration.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent use may reduce efficacy of either product. - Immunosuppressive therapy: may diminish the immune response to the vaccine. - Antihistamines: may mask early signs of an allergic reaction.

Moderate Interactions (Monitor Closely): - Antipyretics: may blunt post‑vaccination fever and reduce reactogenicity. - Corticosteroids: may affect antibody production and overall vaccine effectiveness. - Blood thinners: monitor injection site for prolonged bleeding or bruising.

Frequently asked questions

What is Nuvaxovid Xbb.1.5 used for?+
Nuvaxovid Xbb.1.5 is an intramuscular vaccine that targets emerging viral pathogens. It is intended to provide prophylactic immunity against newly identified viruses and to support public health initiatives during outbreak or pandemic situations.
How does Matrix M work in Nuvaxovid Xbb.1.5?+
Matrix M, together with Mivalsecovatein, acts as a recombinant protein antigen. After injection, the antigens are processed by antigen‑presenting cells, which activate B‑cells and T‑cells, leading to the production of specific antibodies and cellular immunity against the targeted virus.
What is the usual dose of Nuvaxovid Xbb.1.5?+
The dosing regimen for Nuvaxovid Xbb.1.5 is determined by the prescribing clinician based on the patient’s age, health status, and the specific indication. Healthcare professionals should follow the latest clinical guidelines and product labeling when prescribing.
Is Nuvaxovid Xbb.1.5 safe during pregnancy or breastfeeding?+
Safety data for Nuvaxovid Xbb.1.5 in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before administering the vaccine to pregnant or breastfeeding individuals.
How do I order Nuvaxovid Xbb.1.5 from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.
How does Nuvaxovid Xbb.1.5 compare with other viral vaccines?+
Nuvaxovid Xbb.1.5 uses the proprietary Matrix M and Mivalsecovatein antigens, which differ from traditional inactivated or live‑attenuated vaccines. Its design aims to elicit a broad immune response and may offer advantages in speed of development for emerging viruses, though comparative efficacy depends on the specific pathogen and clinical trial data.
What are the storage and handling requirements for Nuvaxovid Xbb.1.5?+
The vaccine must be stored refrigerated between 2 °C and 8 °C. It should be kept in the original packaging, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport and storage is essential to preserve potency.
How is Nuvaxovid Xbb.1.5 administered?+
Nuvaxovid Xbb.1.5 is given as a single intramuscular injection, typically into the deltoid muscle. Administration should be performed by a qualified healthcare professional using aseptic technique and following local immunization guidelines.
What are the most serious risks associated with Nuvaxovid Xbb.1.5?+
Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, and other severe allergic reactions. Recipients should be observed for at least 15 minutes after injection, and any signs of severe reaction should be treated promptly.
Who should not receive Nuvaxovid Xbb.1.5?+
Individuals with a known severe allergy to any component of the vaccine, or those who have experienced a previous severe reaction to a similar vaccine, should avoid receiving Nuvaxovid Xbb.1.5. Clinicians should also assess contraindications in immunocompromised patients on a case‑by‑case basis.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Matrix M, Mivalsecovatein
Route
Intramuscular Use
Manufacturer
Novavax Cz A.S.
Origin
EU

Related products

Nuvaxovid Xbb.1.5

Nuvaxovid Xbb.1.5

Matrix M, Mivalsecovatein

Novavax Cz A.S.
EU
Nuvaxovid Xbb.1.5

Nuvaxovid Xbb.1.5

Matrix M, Mivalsecovatein

Novavax Cz A.S.
EU
Nuvaxovid Xbb.1.5

Nuvaxovid Xbb.1.5

Matrix M, Mivalsecovatein

Novavax Cz A.S.
EU